^
    21h
    KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Calquence (acalabrutinib)
    1d
    Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma. (PubMed, World J Gastroenterol)
    Comparative insights highlight the advantages of liso-cel over other CAR-T cell products, such as axicabtagene ciloleucel and tisagenlecleucel in terms of toxicity, logistics, and outpatient feasibility. With ongoing improvements in manufacturing, accessibility, and biomarker development, liso-cel is well-positioned to become a central component in the evolving treatment paradigm for FL. However, challenges remain regarding durability of response, cost, and access, which warrant careful discussion.
    Review • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T)
    1d
    Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol. (PubMed, Adv Radiat Oncol)
    Secondary endpoints include patient-reported quality of life (FACIT-Fatigue scale), response rate at 3 months posttreatment (Lugano criteria), local control, relapse-free survival, and overall survival. Exploratory analyses will evaluate financial toxicity (COST-FACIT questionnaire), health care expenditure, late toxicity, and the prognostic value of preradiation metabolic imaging parameters, including metabolic tumor volume, total lesion glycolysis, and maximum standardized uptake value, as well as molecular biomarkers such as TP53, MYC, and Ki-67.
    Clinical • P2 data • Journal
    |
    TP53 (Tumor protein P53)
    1d
    Reduced Activity of Soluble Fibroblast Activation Protein (sFAP) Represents a Biomarker of Aggressive Disease in Lymphoid Malignancies. (PubMed, Int J Mol Sci)
    Interestingly, measuring intratumoral FAP levels revealed an inverse pattern, with diffuse large B-cell lymphoma showing higher tissue FAP localization compared with follicular lymphoma (p < 0.001). These findings provide new insights into the biological and clinical significance of FAP in lymphoid malignancies, particularly highlighting the importance of sFAP activity as a potential prognostic marker in aggressive lymphoid malignancies.
    Journal
    |
    FAP (Fibroblast activation protein, alpha)
    1d
    Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=29, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    lenalidomide • Epkinly (epcoritamab-bysp)
    2d
    Long-term Follow up Local Registry Study of Kymriah in South Korea (clinicaltrials.gov)
    P=N/A, N=179, Recruiting, Novartis Pharmaceuticals | N=500 --> 179
    Enrollment change
    |
    Kymriah (tisagenlecleucel-T)
    3d
    Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) (clinicaltrials.gov)
    P2, N=155, Active, not recruiting, Daiichi Sankyo | Trial completion date: Sep 2025 --> Feb 2027
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • CD8 (cluster of differentiation 8)
    |
    ALK positive • ALK negative
    |
    Ezharmia (valemetostat)
    4d
    M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=340, Recruiting, AbbVie | N=244 --> 340
    Enrollment change • Adverse events • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive
    |
    ABBV-101
    6d
    A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov)
    P1, N=20, Recruiting, Janssen Research & Development, LLC | Trial completion date: Feb 2039 --> Jan 2040
    Trial completion date
    |
    JNJ-9530
    7d
    Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight. (PubMed, Hematology Am Soc Hematol Educ Program)
    From a safety perspective, much progress has been made in reducing the burden of side effects and broadening access; however, barriers remain before TCE therapies can be widely available to all patients. This brief review addresses some of the latest strategies being tested to elevate TCE therapies as pillars of immunotherapy for B-NHL.
    Review • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    8d
    BELLWAVE-003: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (clinicaltrials.gov)
    P2, N=490, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2027 --> Jan 2029 | Trial primary completion date: Mar 2027 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CD4 (CD4 Molecule)
    |
    TP53 mutation • Chr t(11;14)
    |
    nemtabrutinib (MK-1026)
    10d
    FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. (PubMed, J Clin Oncol)
    The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.
    Journal
    |
    B2M (Beta-2-microglobulin)